Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction
Go back to Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland DysfunctionCBC Holding Company (NYSE: BHC) | Delayed: 10.61 +0.12 (1.14%) | |||||
---|---|---|---|---|---|---|
Previous Close | $10.49 | 52 Week High | $4.75 | |||
Open | $10.46 | 52 Week Low | $4.75 | |||
Day High | $10.80 | P/E | N/A | |||
Day Low | $10.45 | EPS | $0.00 | |||
Volume | 3,815,212 |
CBC Holding Company (NYSE: BHC) | Delayed: 10.61 +0.12 (1.14%) | |||||
---|---|---|---|---|---|---|
Previous Close | $10.49 | 52 Week High | $4.75 | |||
Open | $10.46 | 52 Week Low | $4.75 | |||
Day High | $10.80 | P/E | N/A | |||
Day Low | $10.45 | EPS | $0.00 | |||
Volume | 3,815,212 |
VALEANT PHARMACEUTICALS INTERNATIONAL (NYSE: VRX) | Delayed: 23.40 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $23.40 | 52 Week High | $119.86 | |||
Open | $23.40 | 52 Week Low | $13.77 | |||
Day High | $23.40 | P/E | N/A | |||
Day Low | $23.40 | EPS | $0.00 | |||
Volume | 378,733 |